|
1
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chauhan D, Hideshima T, Mitsiades C,
Richardson P and Anderson KC: Proteasome inhibitor therapy in
multiple myeloma. Mol Cancer Ther. 4:686–692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hideshima T, Mitsiades C, Akiyama M,
Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi
NC, Mitsiades N and Anderson KC: Molecular mechanisms mediating
anti-myeloma activity of proteasome inhibitor PS-341. Blood.
101:1530–1534. 2003. View Article : Google Scholar
|
|
4
|
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy
MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust
JA, et al: Improved survival in multiple myeloma and the impact of
novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar
|
|
5
|
Moreau P, Attal M and Facon T: Frontline
therapy of multiple myeloma. Blood. 125:3076–3084. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ludwig H, Bolejack V, Crowley J, Bladé J,
Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J,
et al: Survival and years of life lost in different age cohorts of
patients with multiple myeloma. J Clin Oncol. 28:1599–1605. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Decaux O, Lodé L, Magrangeas F, Charbonnel
C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P,
Bataille R, et al: Prediction of survival in multiple myeloma based
on gene expression profiles reveals cell cycle and chromosomal
instability signatures in high-risk patients and hyperdiploid
signatures in low-risk patients: A study of the Intergroupe
Francophone du Myélome. J Clin Oncol. 26:4798–4805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gutiérrez NC, Sarasquete ME,
Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV,
Fermiñán E, Martín-Jiménez P, Chillón C, Risueño A, et al:
Deregulation of microRNA expression in the different genetic
subtypes of multiple myeloma and correlation with gene expression
profiling. Leukemia. 24:629–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Walker BA, Wardell CP, Chiecchio L, Smith
EM, Boyd KD, Neri A, Davies FE, Ross FM and Morgan GJ: Aberrant
global methylation patterns affect the molecular pathogenesis and
prognosis of multiple myeloma. Blood. 117:553–562. 2011. View Article : Google Scholar
|
|
10
|
San-Miguel J, García-Sanz R and
López-Pérez R: Analysis of methylation pattern in multiple myeloma.
Acta Haematol. 114(Suppl 1): 23–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Curran MP: Decitabine: A review of its use
in older patients with acute myeloid leukaemia. Drugs Aging.
30:447–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jabbour E, Issa JP, Garcia-Manero G and
Kantarjian H: Evolution of decitabine development: Accomplishments,
ongoing investigations, and future strategies. Cancer.
112:2341–2351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nie J, Liu L, Li X and Han W: Decitabine,
a new star in epigenetic therapy: The clinical application and
biological mechanism in solid tumors. Cancer Lett. 354:12–20. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Primeau M, Gagnon J and Momparler RL:
Synergistic antineoplastic action of DNA methylation inhibitor
5-AZA-2′-deoxycytidine and histone deacetylase inhibitor
depsipeptide on human breast carcinoma cells. Int J Cancer.
103:177–184. 2003. View Article : Google Scholar
|
|
15
|
Numoto K, Yoshida A, Sugihara S, Kunisada
T, Morimoto Y, Yoneda Y, Fujita Y, Nishida K, Ouchida M and Ozaki
T: Frequent methylation of RASSF1A in synovial sarcoma and the
anti-tumor effects of 5-aza-2′-deoxycytidine against synovial
sarcoma cell lines. J Cancer Res Clin Oncol. 136:17–25. 2010.
View Article : Google Scholar
|
|
16
|
Wang L, Amoozgar Z, Huang J, Saleh MH,
Xing D, Orsulic S and Goldberg MS: Decitabine enhances lymphocyte
migration and function and synergizes with CTLA-4 blockade in a
murine ovarian cancer model. Cancer Immunol Res. 3:1030–1041. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Turcan S, Fabius AW, Borodovsky A, Pedraza
A, Brennan C, Huse J, Viale A, Riggins GJ and Chan TA: Efficient
induction of differentiation and growth inhibition in IDH1 mutant
glioma cells by the DNMT inhibitor Decitabine. Oncotarget.
4:1729–1736. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding L, Qiu L, Zhang J and Guo B:
Camptothecin-induced cell proliferation inhibition and apoptosis
enhanced by DNA methyltransferase inhibitor,
5-aza-2′-deoxycytidine. Biol Pharm Bull. 32:1105–1108. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann
E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, et al:
Bortezomib induces DNA hypomethylation and silenced gene
transcription by interfering with Sp1/NF-kappaB-dependent DNA
meth-yltransferase activity in acute myeloid leukemia. Blood.
111:2364–2373. 2008. View Article : Google Scholar
|
|
21
|
Leshchenko VV, Kuo PY, Jiang Z, Weniger
MA, Overbey J, Dunleavy K, Wilson WH, Wiestner A and Parekh S:
Harnessing Noxa demethylation to overcome Bortezomib resistance in
mantle cell lymphoma. Oncotarget. 6:27332–27342. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blum W, Schwind S, Tarighat SS, Geyer S,
Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R,
et al: Clinical and pharmacodynamic activity of bortezomib and
decitabine in acute myeloid leukemia. Blood. 119:6025–6031. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Adams J: The proteasome: A suitable
antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cecarini V, Bonfili L, Cuccioloni M,
Mozzicafreddo M, Rossi G, Buizza L, Uberti D, Angeletti M and
Eleuteri AM: Crosstalk between the ubiquitin-proteasome system and
autophagy in a human cellular model of Alzheimer's disease. Biochim
Biophys Acta. 1822:1741–1751. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bassermann F, Eichner R and Pagano M: The
ubiquitin proteasome system-implications for cell cycle control and
the targeted treatment of cancer. Biochim Biophys Acta.
1843:150–162. 2014. View Article : Google Scholar
|
|
26
|
Neutzner A, Li S, Xu S and Karbowski M:
The ubiquitin/proteasome system-dependent control of mitochondrial
steps in apoptosis. Semin Cell Dev Biol. 23:499–508. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yerlikaya A and Yöntem M: The significance
of ubiquitin proteasome pathway in cancer development. Recent Pat
Anticancer Drug Discov. 8:298–309. 2013. View Article : Google Scholar
|
|
28
|
Gatto S, Scappini B, Pham L, Onida F,
Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM,
et al: The proteasome inhibitor PS-341 inhibits growth and induces
apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to
imatinib mesylate. Haematologica. 88:853–863. 2003.PubMed/NCBI
|
|
29
|
Patrizi A, Venturi M, Dika E, Maibach H,
Tacchetti P and Brandi G: Cutaneous adverse reactions linked to
targeted anticancer therapies bortezomib and lenalidomide for
multiple myeloma: New drugs, old side effects. Cutan Ocul Toxicol.
33:1–6. 2014. View Article : Google Scholar
|
|
30
|
Cho Y, Hori M, Okoshi Y, Fujisawa F,
Shinagawa A, Kudo D, Komeno T, Yoshida C, Katsura Y, Ota I, et al:
Measurement of proteasome activity in peripheral blood mononuclear
cells as an indicator of susceptibility to bortezomib-induced
severe neurological adverse events in patients with multiple
myeloma. Acta Haematol. 134:25–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D,
Lonial S, San Miguel JF, et al: Safety and efficacy of bortezomib
in high-risk and elderly patients with relapsed multiple myeloma.
Br J Haematol. 137:429–435. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li E and Zhang Y: DNA methylation in
mammals. Cold Spring Harb Perspect Biol. 6:a0191332014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
34
|
Kaiser MF, Johnson DC, Wu P, Walker BA,
Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE and Morgan
GJ: Global methylation analysis identifies prognostically important
epigenetically inactivated tumor suppressor genes in multiple
myeloma. Blood. 122:219–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
de Carvalho F, Colleoni GW, Almeida MS,
Carvalho AL and Vettore AL: TGFbetaR2 aberrant methylation is a
potential prognostic marker and therapeutic target in multiple
myeloma. Int J Cancer. 125:1985–1991. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Galm O, Yoshikawa H, Esteller M, Osieka R
and Herman JG: SOCS-1, a negative regulator of cytokine signaling,
is frequently silenced by methylation in multiple myeloma. Blood.
101:2784–2788. 2003. View Article : Google Scholar
|
|
37
|
Mateos MV, Garcia-Sanz R, López-Pérez R,
Moro MJ, Ocio E, Hernández J, Megido M, Caballero MD,
Fernández-Calvo J, Bárez A, et al: Methylation is an inactivating
mechanism of the p16 gene in multiple myeloma associated with high
plasma cell proliferation and short survival. Br J Haematol.
118:1034–1040. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takada S, Morita K, Hayashi K, Matsushima
T, Sawamura M, Murakami H and Nojima Y: Methylation status of
fragile histidine triad (FHIT) gene and its clinical impact on
prognosis of patients with multiple myeloma. Eur J Haematol.
75:505–510. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Robert MF, Morin S, Beaulieu N, Gauthier
F, Chute IC, Barsalou A and MacLeod AR: DNMT1 is required to
maintain CpG methylation and aberrant gene silencing in human
cancer cells. Nat Genet. 33:61–65. 2003. View Article : Google Scholar
|
|
41
|
Tsai HC, Li H, Van Neste L, Cai Y, Robert
C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al:
Transient low doses of DNA-demethylating agents exert durable
antitumor effects on hematological and epithelial tumor cells.
Cancer Cell. 21:430–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
